Clinical Trials

MONTREAL, Aug. 28 /CNW Telbec/ - Immunotec Inc. (TSX-V: IMM) announced today the completion of an open-label clinical trial on the use of a cysteine-rich protein isolate in children with autism. Ten children, 3-15 years of age with a diagnosis of...

BETHESDA, Md., Aug. 27, 2008--A brain chemical that plays a role in long term memory also appears to be involved in regulating how much people eat and their likelihood of becoming obese, according to a National Institutes of Health study of a rare...

  Further validation of Heptares' StaRT technology LONDON, Aug. 28, 2008--Heptares Therapeutics Ltd, the drug discovery company focused on the design and development of novel drugs based on G-protein-coupled receptors (GPCRs), notes that a new...

Results Presented at the Australian and New Zealand Bone and Mineral Society (ANZBMS) Annual Meeting HOPKINTON, Mass., Aug. 28 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc., , announced that data from preclinical studies of the Company's...

WARREN, N.J.--(BUSINESS WIRE)--Aug 28, 2008 - In patients with diabetes, the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus(R) Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area),...

COLUMBIA, Md.--(BUSINESS WIRE)--Aug. 28, 2008 - CELSION CORPORATION (NASDAQ: CLSN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox(R) used in combination with Radio Frequency Ablation...

- Patients in the VELCADE, melphalan and prednisone arm demonstrated a significant survival benefit as well as a 30 percent complete response - CAMBRIDGE, Mass., August 27, 2008 /PRNewswire/ -- Millennium: The Takeda Oncology Company today...

Northwestern Memorial Hospital one of 18 centers involved in 10-year study CHICAGO, August 27, 2008 /PRNewswire-USNewswire/ -- Results of a 10-year study published in the August 28 issue of the New England Journal of Medicine found that magnesium...

Award Winning Research Team Makes Crucial Breakthrough in Battle to Prevent Onset of Parkinson's Disease CHICAGO, August 27, 2008 /PRNewswire/ -- The British Midlands Development Corporation today announced that scientists at The University of...

OSLO, August 28, 2008 /PRNewswire-FirstCall/ -- - Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC) Algeta ASA , the...

Studies demonstrate efficacy and safety of VisonacTM and the potential for a simplified Photodynamic Therapy (PDT) procedure for treatment of moderate to severe acne Oslo, Norway, August 27, 2008 – Photocure announces positive preliminary results...

Study led by Hollings Cancer Center researcher finds risk greatest in ages 25-44 CHARLESTON, S.C., Aug. 26 /PRNewswire/ -- Individuals with a history of nonmelanoma skin cancer (NMSC), especially those who had it at a younger age, are at...

STANFORD, Calif.--(BUSINESS WIRE)--Aug 26, 2008 - Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins. Doctors have known the disease is caused by an autoimmune attack on the pancreas, but the...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 26, 2008 - The Medicines Company (NASDAQ: MDCO) today announced that the results of VELOCITY, a pivotal Phase 3 safety and efficacy trial of its new intravenous (IV) therapy Cleviprex(TM) (clevidipine...

  Studies from pramipexole clinical programme confirm efficacy in treating highly prevalent RLS-associated symptoms, including limb pain and mood disturbance Ingelheim, Germany, 26 August 2008 – Results from a large pramipexole trial programme in...

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness ROCKVILLE, Md., Aug. 26, 2008 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today favorable results from the second stage of...

STOCKHOLM, SWEDEN, August 26, 2008 - Pharmalink AB today announces positive results from a follow-on Phase III study of Xepol®, its candidate for the treatment of post-polio syndrome (PPS). The data have shown the candidate to be effective and...

STANFORD, Calif.--(BUSINESS WIRE)--Aug 26, 2008 - Previously unrecognized and unidentified infections of amniotic fluid may be a significant cause of premature birth, according to researchers at the Stanford University School of Medicine. An...

BALTIMORE, August 26, 2008 /PRNewswire-USNewswire/ -- Data by Dr. Bart Classen in The Open Endocrinology Journal provides further evidence that epidemics of childhood obesity, type 2 diabetes and metabolic syndrome are the result of exposure to the...

JERUSALEM--(BUSINESS WIRE)--Aug 26, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announces that results of the phase III ADAGIO trial were presented today during the 12th Congress of European Federation of Neurological Societies (EFNS)...